References
- Nam NH , KimY , YouYJ , HongDH , KimHM , AnnBZ. Synthesis, cytotoxicity and antitumor activity of 2, 3-diarylcy-clopent-2-ene-1-ones. Arch. Pharm. Res.25(5), 600–607 (2002).
- Schaefer W , FriebeWG , LeinertHet al. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and x-ray structure investigations. J. Med. Chem.36(6), 726–732 (1993).
- Prasit P , GuayD , WangZ , LegerS , TherienM. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2: US6329421 (1996).
- Yonova IM , OsborneCA , MorrissetteNS , JarvoER. Diaryl and heteroaryl sulfides: synthesis via sulfenyl chlorides and evaluation as selective anti-breast-cancer agents. J. Org. Chem.79(5), 1947–1953 (2014).
- Barreca ML , BalzariniJ , ChimirriAet al. Design, synthesis, structure−activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J. Med. Chem.45(24), 5410–5413 (2002).
- Pauwels R , AndriesK , DebyserZet al. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl Acad. Sci. USA90(5), 1711–1715 (1993).
- Tian Y , ZhanP , RaiD , ZhangJ , DeClercq E , LiuX. Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem.19(13), 2026–2037 (2012).
- Rao A , CarboneA , ChimirriAet al. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi) one derivatives. Farmaco57(9), 747–751 (2002).
- Rawal RK , TripathiRK , KattiS , PannecouqueC , DeClercq E. Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4-ones as anti-HIV agents. Med. Chem.3(4), 355–363 (2007).
- Rawal RK , SolomonVR , PrabhakarYS , KattiS , DeClercq E. Synthesis and QSAR studies on thiazolidinones as anti-HIV agents. Comb. Chem. High Throughput Screen.8(5), 439–443 (2005).
- Kim Y , NamNH , YouYJ , AhnBZ. Synthesis and cytotoxicity of 3,4-diaryl-2(5H)-furanones. Bioorg. Med. Chem. Lett.12(4), 719–722 (2002).
- Ramajayam R , GiridharR , YadavMet al. Synthesis, antileukemic and antiplatelet activities of 2,3-diaryl-6,7-dihydro-5H-1,4-diazepines. Eur. J. Med. Chem.43(9), 2004–2010 (2008).
- Pommery N , TaverneT , TelliezAet al. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J. Med. Chem.47(25), 6195–6206 (2004).
- Kurumbail RG , StevensAM , GierseJKet al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature384(6610), 644 (1996).
- Mason RP , WalterMF , McNultyHPet al. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J. Cardiovasc. Pharmacol.47, S7–S14 (2006).
- Weber A , CasiniA , HeineAet al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem.47(3), 550–557 (2004).
- Carter JS , KramerS , TalleyJJet al. Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett.9(8), 1171–1174 (1999).
- Yadav M , ShirudeS , ParmarA , BalaramanR , GiridharR. Synthesis and anti-inflammatory activity of 2,3-diaryl-4(3H)-quinazolinones. Chem. Heterocycl. Compd.42(8), 1038–1045 (2006).
- Lansdon EB , BrendzaKM , HungMet al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem.53(10), 4295–4299 (2010).
- Chen Y , JobanputraP , BartonPet al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. In: NIHR Health Technology Assessment programme: Executive Summaries.NIHR Journals Library, Southampton, UK (2008).
- Beer TM , ArmstrongAJ , RathkopfDEet al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med.371(5), 424–433 (2014).